{"brief_title": "Study of ONTAK in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL)", "brief_summary": "The purpose of this study is to evaluate the safety and effectiveness of ONTAK in previously treated patients with chronic lymphocytic leukemia (CLL)", "condition": ["Leukemia, Lymphocytic, Chronic"], "intervention_type": ["Drug"], "intervention_name": ["ONTAK"], "criteria": "Inclusion Criteria: - Patients with B-cell Chronic Lymphocytic Leukemia, Rai Stage 0-II with indication for treatment by NCI Working Group Criteria or Rai Stage III or IV. - Patients must have received at least one prior purine analogue-based chemotherapy regimen. - ECOG Performance Status of 0, 1, or 2. - Female patients cannot be pregnant and must use birth control during the course of the study and for three weeks after the study ends. Exclusion Criteria: - Prior treatment with ONTAK (DAB389IL-2) or DAB486IL-2. - Received any therapy for CLL within 35 days prior to study entry.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "mesh_term": ["Leukemia", "Leukemia, Lymphoid", "Leukemia, Lymphocytic, Chronic, B-Cell", "Denileukin diftitox"], "id": "NCT00055146"}